

HLS Therapeutics Inc.

HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 18, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 18, 2021.

A total of 28,701,084 Common Shares, or 89.70% of the total Common Shares issued and outstanding, were voted by proxy at the meeting. Details of the voting by individual director were as follows:

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
William Wells	26,239,157	98.42%	421,208	1.58%
Gilbert Godin	26,658,368	99.99%	1,997	0.01%
Greg Gubitz	26,657,885	99.99%	2,480	0.01%
J. Spencer Lanthier	24,305,484	91.17%	2,354,881	8.83%
Yvon Bastien	25,238,694	94.67%	1,421,671	5.33%
Rodney Hill	22,879,834	85.82%	3,780,531	14.18%
Don DeGolyer	25,241,351	94.68%	1,419,014	5.32%
Laura Brege	22,873,887	85.80%	3,786,478	14.20%
John Welborn	26,630,363	99.89%	30,002	0.11%
Norma Beauchamp	26,623,535	99.86%	36,830	0.14%

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company's auditors as well as an ordinary resolution approving certain proposed amendments to the Company's Stock Option Plan and approving the unallocated options thereunder.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

For further information: Dave Mason, Investor Relations, 416.247.9652, d.mason@hlstherapeutics.com

<https://hlstherapeutics.investorroom.com/2021-06-18-HLS-Therapeutics-Reports-Annual-Meeting-Results>